Back to Overview
Dr. Bernd Fabry
Bernd Fabry started his professional career as a lecturer of Organic Chemistry at the FH Jülich before changing to Henkel KGaA in 1986, where he became laboratory manager. In 1990, he began to work in the Patent Department and was Deputy Head of Department until 1999.
- Chemistry & Engineering 100% 100%
- Life Science 25% 25%
- Trademarks 75% 75%
- Employee Inventors Law 100% 100%
German, Englisch, Spanish, French, Dutch
+ 49 2166.398.4651
What more there is to say...
After completing a degree in Chemistry and obtaining a Ph.D. at the RWTH Aachen, Bernd Fabry started his professional career as a lecturer of Organic Chemistry at the FH Jülich before changing to Henkel KGaA in 1986, where he became laboratory manager. In 1990, he began to work in the Patent Department and was Deputy Head of Department until 1999. From 1999 to 2011 he has been Managing Director of Cognis IP Management GmbH with responsibility for IP rights, but also for licenses and regulatory affairs.
For a decade Bernd Fabry was lecturer of IP Management at Otto-Beisheim School of Management in Vallendar; he has authored numerous papers and books in the field of IP protection. He founded IP2 in 2006.
Bernd prefers to spend his limited leisure time together with his big family. Bernd is an enthusiastic amateur chef and the best friend of a good bottle of wine; his less calorie-rich hobbies include cycling, water sports and writing crime novels.
What moves me
Another bad day for bunnies. This time it was the purple milk bunny and for a change it was not about the infringement of trademark rights, but about a violation of the labeling obligation for food, which the judges at the Bremen Regional Court had to decide on (12 O...
With more than 500 million sold over the past three decades and a market share of over 40 percent (2017), the chocolate bunny in gold foil, red bow and bell is the clear market leader. But there can be no talk of post-Easter peace. Bad karma for gold bunnies in the...
In recent days, politicians and the media have been discussing the possible suspension of patent protection for Covid-19 drugs. However, the reporting suffers from the fact that the actors have little idea of the matter. Is time for a closer look. Can the WHO suspend...
Back to Overview